Clinical Trial of LINGO (BIIB033)
March 26, 2014
Dr. Barry A Hendin at the Phoenix Neurological Associates will be conducting a clinical trial on the efficacy, safety, tolerability, and pharmacokinetics of LINGO (BIIB033) in subjects with relapsing forms of Multiple Sclerosis. LINGO is a human monoclonal antibody directed against LINGO-1, with potential to enhance central nervous system (CNS) repair through remyelination.
For more information please contact:
Lynne E. Flynn, CCRC - Study Coordinator, at 602-258-2863 or email@example.com or call the main line at 602-258-3354
Find more information about other clinical trials.
About the Arizona Chapter of the National Multiple Sclerosis (MS) Society
The Arizona Chapter works tirelessly to improve the quality of life for the 45,500 people affected by MS throughout Arizona. Our mission is to create a world free of multiple sclerosis. We are here for you, your family or anyone you know affected by MS.
About Multiple Sclerosis
Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.